Procter & Gamble Health Ltd Company History

The Company was incorporated on 26th April, as a private limited

company. It was converted into a public limited company on 29th June,

1981. Among the important items manufactured by the Company are

specialities in the group of neurotropics such as encephabol and

anti-psychotics such as lithocarb and vitamin formulations such as

neurobion, polybion, multiboonata, etc.

E. Merck, Darmstadt, West Germany are the Company's collaborators who

had been supplying sophisticated technical know-how to the Company free

of charge.

12,782 No. of shares issued without payment in prop. 1:3.

2,500 bonus shares issued in prop. 1:3.

50,000 Bonus shares issued in prop. 1:2.

The non-resident equity holding in the Company was reduced from 60%

to 51% by the issue of new equity shares to resident equity

shareholders and to the public.

Shares subdivided on 29.6.1981. Issued 5,02,500 shares to Chemitra

GmbH, West Germany and 47,500 shares as Rights to resident Indian

shareholders. 7,02,067 shares (including 2,067 shares not taken up by

the resident Indian shareholders) offered at par for public

subscription during August.

In order to raise funds for working capital requirements, the Company

privately placed with Army Group Insurance Fund 1,00,000 - 15%

non-convertible debentures of Rs 100 each. These debentures are

redeemable at a premium of 5% on 12th August, 1992. The Company also

privately placed with UTI 2,00,000 - 15% non-convertible redeemable

debentures of Rs 100 each aggregating Rs 200 lakhs. These debentures

were to be redeemed at a premium of 5% after the expiry of 7 years from

the date of allotment.

Several essential drugs like Praziquantel, Septopal Beads and

anti-cancer drugs were introduced. Soon, the Company intended to

introduce anti-malarial and anti-inflammatory drugs.

16,50,000 bonus equity shares issued in prop. 3:5.

A bulk drug unit, at Indore, manufacturing chloroquine phosphate and

its derivatives was acquired by the Company.

The Company acquired a significant shareholding in Suneeta

Laboratories, Indore, equipped with strong scientific base and

professionals, with a view to manufacturing several active ingredients.

15,40,000 shares issued (prem. Rs 10 per share); 14,66,667 shares as

Rights in Prop. 1:3 (only 14,39,924 shares) taken up and (ii) 73,333

shares to employees (all were taken up). The 26,743 shares not taken

up out of Rights quota were allotted privately.

The Company launched its diagonistics project.

A new pharmaceutical formulation division was launched to market

formulations bearing BDH trade mark.

During March-April, the Company offered 5,50,000-14% secured

redeemable non-convertible debentures of Rs 100 each for cash at par on

The name of the Company was changed to BDH Pharmaceuticals, Ltd. The

unit is manufacturing and marketing certain bulk drugs viz.

chloroquine phosphate and chloroquin sulphate. The Company sold its

Indore plant at a total consideration of Rs 200 lakhs to BDH Pharma,

both from the point of view of locational disadvantages of having a

plant at Indore and from the point of view of control.

29,70,000 Bonus equity shares issued in prop. 1:2.

During March, the Company offered 5,55,428 - zero interest fully

convertible debentures of Rs 120 each on Rights basis in the proportion

1 debenture: 10 equity shares held (all were taken up). Simultaneously

another 27,772 debentures were issued to the employees on an equitable

basis (all were taken up). Debentures under category (i) and (ii) were

taken up.

The Company also issued the following zero interest fully convertible

debentures of Rs 120 each to foreign promoters to maintain their

holding to the extent of 40% in the Company:

(i) 2,49,500 debentures to Emedia Export Company GmbH and

(ii) 1,39,300 debentures to Chemilia, GmbH. Debentures under

category (i) and (ii) were taken up. Each of the above mentioned zero

interest debentures are to be converted into five equity shares of Rs

10 each at a premium of Rs 14 per share on 7th January, 1993.

The poor performance in the national and international market was

attributed to sale of Indore plant manufacturing chloroquine phosphate

and other items, and decrease in offtake of Guaiazulene to Japan

respectively.

During May, the Company issued and allotted 30,91,224 new equity

shares of Rs 10 each at a premium of Rs 14 per share to Merck AG or

their Associates to increase their stake in the Company from the

existing 40% to 51%.

During August, the Company had redeemed 14% NCD's, (Series 11)

aggregating to Rs 55 million. During February 1998, the Company had

redeemed one-third (second instalment) of the 16.5% NCD's aggregating

to Rs 20 million held by UTI.

Taloja plant setting up a soft gelatin capsule plant in Goa and the

parent E Merck of the US recently set up a 100 per cent subsidiary.

Almost all the non-pharma capacity of EMIL is being utilised and the

company is already sourcing its higher needs through loan licence

agreements with smaller manufacturers.

EMI, a 51-per-cent subsidiary of E Merck, Germany, has five divisions

pharma, reagents, bulk drugs, diagnostics and pigments.

E Merck (India) has assigned its popular vitamin-B complex syrup

brand Polybion to a small scale manufacturer, facilitating its removal

from the clutches of price control.

E Merck is unlikely to opt for the joint venture route for the OTC

business and would build on its own distribution strength in contrast

to other drug companies like Nicholas Pirmala.

E Merck India is one of the largest players in the vitamins market.

Buoyed by the international acquisition of a $50 million laboratory

chemicals company by its parent, E Merck India will soon be able to

introduce a range of premium laboratory chemicals that will facilitate

research in biotechnology in the country.

E.Merck, a subsidiary of Merck of Germany and domestic pharma company

Kopran have entered into a co-markering arrangement for cardiovascular

drug atorvastatin.

E.Merck (India) Ltd has informed that Prof. Thomas Schereckenbach has

been appointed as Additional Director. And Mr.K. J.Mallya has been

appointed as the Company Secretary of the Company on November 19, 2001

and he will also be the Compliance Officer of the Company.

Merck signs Deed of Assignment with Biochem Pharmaceuticals

Merck Ltd has appointed Mr. K Shivkumar as an Additional Director.

Merck Ltd has informed that at the Meeting of the Board of Directors held on July 20, 2009 Mr. Ralph Antonius Zaat has been appointed as a Director in place of Dr. Hans Hermansson.

The Company at its meeting held on January 22, 2010, inter alia, has recommended a final dividend of Rs. 20/- per share.

Merck KGaA and sanofi-aventis Sign Agreement to Jointly Investigate Novel Combinations Against Cancer.

Merck KGaA Donation Program Supports Schistosomiasis Control in Africa.

FDA Approves Egrifta (tesamorelin for injection): First and Only Treatment for the Reduction of Excess Abdominal Fat in HIV-infected Patients with Lipodystrophy.

Merck KGaA Intends to Name Matthias Zachert to Executive Board.

Merck Appoints Frederic Wohlwend as CIO.

Merck Strengthens Research Cooperation With Israel.

Merck Received European Approval for Three Pre-filled, Ready-to-use Pen Injectors for Fertility Treatment.

Merck Donates100 Millionth Tablet to Treat Schistosomiasis.

Standard & Poor’s Raises Merck’s Long-Term Credit Rating to A- with Stable Outlook.

Merck Advances to Eighth Place in the 2012 Access to Medicine Index.

Jon Baumhauer Awarded the Luther Rose.

Merck Serono Announces Final Efficiency Program for Switzerland.

Merck Invests in Research Partnerships in Israel to Boost Innovation.

Merck Serono announced the formation of the global Oncology Partnership and Education Network (OPEN).

Merck Ltd has changed Corporate Office moved to a new location. The Company's address and contact details are given below.MERCK LIMITED Godrej One, 8th floor Pirojshanagar,Eastern Express Highway,Vikhroli(E), Mumbai 400079.

Merck Acquires Ormet Circuits

Merck Helps Refugees in Lebanon

Merck and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelumab

Merck and Pfizer Receive Positive Opinion for Orphan Drug Designation for Avelumab in Merkel Cell Carcinoma from EMA Committee for Orphan Medicinal Products

Merck Expands Distribution Agreement with Roche

Merck Wins R&D 100 Award for Top Invention

Merck Sets its Sights on 2018 and Outlines Future Strategic Roadmap

Merck Presents Its First Russian Literary Prize

P&G Acquires the Consumer Health Business of Merck KGaA, Darmstadt, Germany.

P&G Health launches PANACHE for India’s Gen X doctors a first of its kind platform to assist medical students on all round knowledge of healthcare.

P&G Health partners with PHFI to implement Digital Health Project at Goa under its ‘SEHAT’ CSR Program.

PG Health partners with Tata Trusts to advance the nutritional status of women and children in Andhra Pradesh.

P&G Health commemorates Iron Deficiency Day with a new "GUINNESS WORLD RECORDS" Achievement.

P&G Health's "Na Na Anemia Bus Yatra" to travel across 20 cities to raise awareness around Iron Deficiency Anemia.

P&G Health partners with Lakshya and Recycle India Foundation to promote sustainable pharmacy waste segregation and management.

P&G Health Brings Global Nerve Care Experts Together to highlight concerns and help raise Awareness around Peripheral Neuropathy.

P&G Health partners with Apnalaya to improve maternal, newborn health in Mumbai's urban slums.

P&G Health joins hands with Indian Academy of Pediatrics (IAP) for Sankalp: Sampoorna Swasthya a school based holistic healthcare initiative.

P&G Health Launched Mobile Healthcare Unit in Partnership with HelpAge India in Guwahati.

P&G Health collaborates with the Indian Medical Association, launched VitaM.I.N.D.S conclave.

Polybion celebrated World Health Day, launched ‘Pragati Utsav’ to raise awareness on Vitamin B Deficiency.